Tech Company Financing Transactions
CoMentis Funding Round
On 9/19/2005, CoMentis raised $5.7 million in Series A investment from Sanderling Ventures and Life Science Angels.
Transaction Overview
Company Name
Announced On
9/19/2005
Transaction Type
Venture Equity
Amount
$5,690,000
Round
Series A
Investors
Sanderling Ventures (Lead Investor) (Robert McNeil)
Life Science Angels (Allan May)
Proceeds Purpose
Capital raised in this round will be used to take our two lead drug candidates into human clinical trials in 2006. This new angiogenesis pathway gives us a great opportunity to develop novel, orally active drugs for AMD and cancer, and to tackle the problem of non-healing wounds.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
400 Oyster Point Blvd. 226
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Not Recorded
Overview
CoMentis is a biotech company engaged in the research and development of small molecule drugs to treat neurovascular diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Terence Kelly
VP - General Counsel
Daniel Hunt
VP - R & D
John Ng
Browse more venture capital transactions:
Prev: 9/16/2005: Acura Pharmaceuticals venture capital transaction
Next: 9/19/2005: VeraLight venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to record tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs